Broxuridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Broxuridine
Accession Number
DB12028
Type
Small Molecule
Groups
Investigational
Description

Broxuridine has been used in trials studying the treatment of Leukemia, Stage I Prostate Cancer, Stage IIB Prostate Cancer, and Stage IIA Prostate Cancer.

Structure
Thumb
Synonyms
  • BROMODEOXYURIDINE
External IDs
NSC-38297
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
G34N38R2N1
CAS number
59-14-3
Weight
Average: 307.098
Monoisotopic: 305.985134119
Chemical Formula
C9H11BrN2O5
InChI Key
WOVKYSAHUYNSMH-RRKCRQDMSA-N
InChI
InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
IUPAC Name
5-bromo-4-hydroxy-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
SMILES
[H][[email protected]]1(O)C[[email protected]@]([H])(O[[email protected]]1([H])CO)N1C=C(Br)C(O)=NC1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Broxuridine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Broxuridine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Broxuridine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Broxuridine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Broxuridine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Broxuridine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Broxuridine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Broxuridine.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Broxuridine.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Broxuridine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Broxuridine.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Broxuridine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
ChemSpider
5813
BindingDB
50207303
ChEBI
472552
ChEMBL
CHEMBL222280
HET
U33
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentStage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer1
2Unknown StatusTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.48 mg/mLALOGPS
logP-0.9ALOGPS
logP-0.32ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)6.5ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area102.59 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity58.99 m3·mol-1ChemAxon
Polarizability24.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Nucleosides, nucleotides, and analogues
Sub Class
Pyrimidine nucleosides
Direct Parent
Pyrimidine 2'-deoxyribonucleosides
Alternative Parents
Pyrimidones / Halopyrimidines / Hydroxypyrimidines / Aryl bromides / Hydropyrimidines / Oxolanes / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds
show 6 more
Substituents
Pyrimidine 2'-deoxyribonucleoside / Halopyrimidine / Hydroxypyrimidine / Pyrimidone / Aryl bromide / Aryl halide / Hydropyrimidine / Pyrimidine / Oxolane / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrimidine 2'-deoxyribonucleoside (CHEBI:472552 )
Drug created on October 20, 2016 15:12 / Updated on September 01, 2017 12:16